AU2011203217B2 — Dipeptidyl peptidase inhibitors
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2013-05-30 · 13y expired
What this patent protects
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising Formula (I), wherein M is N 5 or CR4; QI and Q2 are each independently selected from the group consisting of CO, SO, S02, and C=NR9; and each R…
USPTO Abstract
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising Formula (I), wherein M is N 5 or CR4; QI and Q2 are each independently selected from the group consisting of CO, SO, S02, and C=NR9; and each RI, R2, R3, R4 and R9 are as defined herein. R2 , N M 2 (G9 2725888_1 (GH-Matters) P61937.ALJ.1 sotosmi
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.